ロード中...

Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin

BACKGROUND: There is no proven primary preventive strategy for doxorubicin‐induced subclinical cardiotoxicity (DISC), especially among patients without a cardiovascular (CV) risk. We investigated the primary preventive effect on DISC of the concomitant use of angiotensin receptor blockers (ARBs) or...

詳細記述

保存先:
書誌詳細
出版年:Cancer Med
主要な著者: Lee, Myunhee, Chung, Woo‐Baek, Lee, Ji‐eun, Park, Chan‐Seok, Park, Woo‐Chan, Song, Byung‐Joo, Youn, Ho‐Joong
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2021
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8209607/
https://ncbi.nlm.nih.gov/pubmed/33998163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3956
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!